SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Economic burden related to chemotherapy-related adverse events in patients with metastatic breast cancer in an integrated health care system
3 references·2 citing·20 second hop
Economic burden related to chemotherapy-related adverse events in patients with metastatic breast cancer in an integrated health care system (2016)Economic burden related to chemotherapy-r…Sociodemographic Characteristics of Members of a Large, Integrated Health Care System: Comparison with US Census Bureau Data (2012)Sociodemographic Characterist…INCIDENCE-BASED COST-OF-ILLNESS MODEL FOR METASTATIC BREAST CANCER IN THE UNITED STATES (2012)INCIDENCE-BASED COST-OF-ILLNE…Frequency and Cost of Chemotherapy-Related Serious Adverse Effects in a Population Sample of Women With Breast Cancer (2006)Frequency and Cost of Chemoth…Understanding breast cancer survivors’ financial burden and distress after financial assistance (2020)Understanding breast cancer s…Cost-Effectiveness of Tucatinib in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer From the US and Chinese Perspectives (2020)Cost-Effectiveness of Tucatin…Race/Ethnicity, Gender, and Monitoring Socioeconomic Gradients in Health: A Comparison of Area-Based Socioeconomic Measures—The Public Health Disparities Geocoding Project (2003)Association Between Gender Confirmation Treatments and Perceived Gender Congruence, Body Image Satisfaction, and Mental Health in a Cohort of Transgender Individuals (2018)Mental Health of Transgender and Gender Nonconforming Youth Compared With Their Peers (2018)Epidemiological considerations in transgender health: A systematic review with focus on higher quality data (2020)Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. (2001)External validity of randomised controlled trials: “To whom do the results of this trial apply?” (2005)HealtH ReseaRcH Data foR tHe Real WoRlD: tHe MaRketscan ® Databases (2008)How Medicare’s Payment Cuts For Cancer Chemotherapy Drugs Changed Patterns Of Treatment (2010)The Economic Burden of Toxicities Associated with Cancer Treatment: Review of the Literature and Analysis of Nausea and Vomiting, Diarrhoea, Oral Mucositis and Fatigue (2013)A Cost-Effectiveness Analysis of Adjuvant Trastuzumab Regimens in Early HER2/neu–Positive Breast Cancer (2007)Ten-Year Survival and Cost Following Breast Cancer Recurrence: Estimates from SEER-Medicare Data (2007)The Costs of Treating Breast Cancer in the US (2009)Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States (2016)Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer (2016)The Financial Toxicity of Cancer Treatment: A Pilot Study Assessing Out-of-Pocket Expenses and the Insured Cancer Patient's Experience (2013)Washington State Cancer Patients Found To Be At Greater Risk For Bankruptcy Than People Without A Cancer Diagnosis (2013)Financial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer (2016)Methods for the economic evaluation of health care programmes (1987)Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold (2014)The high price of anticancer drugs: origins, implications, barriers, solutions (2017)
this work references cited by second hop

References

  • 2012Sociodemographic Characteristics of Members of a Large, Integrated Health Care System: Comparison with US Census Bureau Data788 cited
  • 2006Frequency and Cost of Chemotherapy-Related Serious Adverse Effects in a Population Sample of Women With Breast Cancer360 cited
  • 2012INCIDENCE-BASED COST-OF-ILLNESS MODEL FOR METASTATIC BREAST CANCER IN THE UNITED STATES76 cited

Cited by

  • 2020Understanding breast cancer survivors’ financial burden and distress after financial assistance56 cited
  • 2020Cost-Effectiveness of Tucatinib in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer From the US and Chinese Perspectives50 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work